Human Trials

OncoMed’s demcizumab fails to meet primary endpoint in pancreatic cancer trial

OncoMed Pharmaceuticals’ demcizumab (anti-DLL4, OMP-21M18) has failed to meet its primary endpoint in the Phase 2 YOSEMITE clinical trial in combination with Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin bound) plus gemcitabine in previously untreated metastatic pancreatic cancer patients.

Medivir’s CTCL drug remetinostat yields positive data in phase II study

Medivir has reported positive data from its phase II clinical trial of the topical, skin-directed histone deacetylase (HDAC) inhibitor, remetinostat, in early stage Cutaneous T-cell Lymphoma patients.

Burosumab’s pediatric phase 2 studies in X-linked hypophosphatemia yield positive results

Ultragenyx Pharmaceutical and Kyowa Kirin International (KKI), a subsidiary of Kyowa Hakko Kirin (Kyowa Hakko Kirin), have reported positive 64-week data from a pediatric Phase 2 study of burosumab (KRN23) for X-linked hypophosphatemia (XLH) treatment in children aged between five and 12 years.

Allergan to advance Botox trial to third phase for treatment of depression

Allergan announced to advance its wrinkle treatment Botox to third phase after its phase II study showed a partial benefit in treating patients with major depressive disorder (MDD).

Verona doses first patient in cystic fibrosis trial of RPL554

Verona Pharma has enrolled and dosed the first patient in a Phase 2a clinical study to evaluate RPL554, as a treatment option for cystic fibrosis (CF).

Amgen, UCB explore option of second course of treatment with evenity

Amgen and UCB have released results from the fourth year of a Phase 2 study demonstrating the safety and efficacy of a second course of treatment with evenity (romosozumab), an investigational candidate for postmenopausal women with osteoporosis.

Ritter reports topline phase 2b/3 results for lactose intolerance treatment RP-G28

Ritter Pharmaceuticals' lactose intolerance treatment, RP-G28, demonstrated efficacy and clinically meaningful benefit in phase 2b/3 clinical trial.

Summit to extend PhaseOut DMD trial for ezutromid

Summit Therapeutics has announced that, subject to regulatory approval, it will go ahead with the planned extension phase of PhaseOut DMD, a Phase 2 clinical trial studying the utrophin modulator ezutromid.

Akashi gets FDA nod to restart clinical development of DMD drug HT-100

Akashi Therapeutics has secured approval from the US Food and Drug Administration (FDA) to resume clinical development of HT-100 (delayed-release halofuginone) in patients with any of the genetic mutations that cause Duchenne muscular dystrophy (DMD).